Sucampo Pharmaceuticals (SCMP) 15.32 $SCMP
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
Sucampo Announces Resolution of Par Pharmaceutical's ANDA for RESCULA(R)
GlobeNewswire - Wed Feb 11, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo and R-Tech Ueno, Ltd. (RTU), have entered into a stipulation and license agreement with Par Pharmaceutical, Inc. (Par). The agreement states that in limited circumstances, Sucampo or RTU would grant Par a license for a generic version of the RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Par had previously submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting approval to market, sell, and use a generic version of RESCULA.
SCMP: 15.32 (+0.04)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Commit To Buy Sucampo Pharmaceuticals At $12.50, Earn 23.6% Annualized Using Options
at The Street - Mon Feb 09, 10:38AM CST
Investors considering a purchase of Sucampo Pharmaceuticals Inc shares, but tentative about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SCMP: 15.32 (+0.04)
Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:27PM CST
Roche Holding AG (RHHBY) announced positive results from a phase III study, GADOLIN, on leukemia drug Gazyva for indolent non-Hodgkin's lymphoma.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 2:31PM CST
Positive news flowed in for BioSpecifics Technologies Corp. (BSTC) when Swedish Orphan Biovitrum AB received approval from the European Commission to market Xiapex for an additional indication.
ENDP: 84.01 (+1.12), BSTC: 38.14 (-0.85), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will present, via "fireside chat" format, at the 2015 Leerink Global Healthcare Conference taking place Thursday, February 12, 2015 at 2:40 PM Eastern Time.
SCMP: 15.32 (+0.04)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:07PM CST
Novartis A.G. (NVS) recently announced that its ophthalmology unit Alcon has received FDA approval for the ophthalmic solution Pazeo (olopatadine hydrochloride solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), NVS: 102.20 (-0.17)
Sucampo names Andrew Smith as CFO
M2 - Mon Feb 02, 6:37AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP) revealed on Friday that it has appointed Andrew Smith, FCMA, CGMA as its chief financial officer.
SCMP: 15.32 (+0.04)
Sucampo Pharmaceuticals announces Mutual Recognition Procedure outcome for AMITIZA for approval in Europe
M2 - Mon Feb 02, 5:15AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP) disclosed on Friday that it has completed the European Mutual Recognition Procedure (MRP) for AMITIZA for the treatment of chronic idiopathic constipation in select European countries.
SCMP: 15.32 (+0.04)
Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO
GlobeNewswire - Fri Jan 30, 3:02PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the appointment of Andrew Smith, FCMA, CGMA to Chief Financial Officer. Mr. Smith previously served as Sucampo's Vice President, Operations & Finance and has over 30 years of financial and accounting experience within the pharmaceutical, biotechnology and medical device industries in companies ranging from start-ups to multinationals, as well as in public accounting.
SCMP: 15.32 (+0.04)
AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
GlobeNewswire - Fri Jan 30, 5:44AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the successful completion of the European Mutual Recognition Procedure (MRP) for AMITIZA (lubiprostone) for the treatment of chronic idiopathic constipation in select European countries, resulting in a recommendation for marketing authorization.
SCMP: 15.32 (+0.04)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Can The Uptrend Continue for Sucampo (SCMP)?
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:06PM CST
Pacira Pharmaceuticals Inc. (PCRX) announced that it has resolved its issue with the FDA related to the promotional aspects of its lead product Exparel.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), PCRX: 113.94 (-0.91)
Sucampo Announces Resolution of Par Pharmaceutical's ANDA for RESCULA(R)
GlobeNewswire - Wed Feb 11, 3:06PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo and R-Tech Ueno, Ltd. (RTU), have entered into a stipulation and license agreement with Par Pharmaceutical, Inc. (Par). The agreement states that in limited circumstances, Sucampo or RTU would grant Par a license for a generic version of the RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Par had previously submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting approval to market, sell, and use a generic version of RESCULA.
SCMP: 15.32 (+0.04)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Commit To Buy Sucampo Pharmaceuticals At $12.50, Earn 23.6% Annualized Using Options
at The Street - Mon Feb 09, 10:38AM CST
Investors considering a purchase of Sucampo Pharmaceuticals Inc shares, but tentative about paying the going market price of $14.68/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
SCMP: 15.32 (+0.04)
Roche Reports Positive Data on Leukemia Drug Gazyva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 5:27PM CST
Roche Holding AG (RHHBY) announced positive results from a phase III study, GADOLIN, on leukemia drug Gazyva for indolent non-Hodgkin's lymphoma.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
BioSpecifics Announces Label Expansion for Xiaflex in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 2:31PM CST
Positive news flowed in for BioSpecifics Technologies Corp. (BSTC) when Swedish Orphan Biovitrum AB received approval from the European Commission to market Xiapex for an additional indication.
ENDP: 84.01 (+1.12), BSTC: 38.14 (-0.85), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 5:45AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will present, via "fireside chat" format, at the 2015 Leerink Global Healthcare Conference taking place Thursday, February 12, 2015 at 2:40 PM Eastern Time.
SCMP: 15.32 (+0.04)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Novartis' Alcon Receives FDA Approval for Pazeo Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:07PM CST
Novartis A.G. (NVS) recently announced that its ophthalmology unit Alcon has received FDA approval for the ophthalmic solution Pazeo (olopatadine hydrochloride solution) 0.7% for the treatment of ocular itching associated with allergic conjunctivitis.
AGN: 229.49 (+1.87), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14), NVS: 102.20 (-0.17)
Sucampo names Andrew Smith as CFO
M2 - Mon Feb 02, 6:37AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP) revealed on Friday that it has appointed Andrew Smith, FCMA, CGMA as its chief financial officer.
SCMP: 15.32 (+0.04)
Sucampo Pharmaceuticals announces Mutual Recognition Procedure outcome for AMITIZA for approval in Europe
M2 - Mon Feb 02, 5:15AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP) disclosed on Friday that it has completed the European Mutual Recognition Procedure (MRP) for AMITIZA for the treatment of chronic idiopathic constipation in select European countries.
SCMP: 15.32 (+0.04)
Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO
GlobeNewswire - Fri Jan 30, 3:02PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the appointment of Andrew Smith, FCMA, CGMA to Chief Financial Officer. Mr. Smith previously served as Sucampo's Vice President, Operations & Finance and has over 30 years of financial and accounting experience within the pharmaceutical, biotechnology and medical device industries in companies ranging from start-ups to multinationals, as well as in public accounting.
SCMP: 15.32 (+0.04)
AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
GlobeNewswire - Fri Jan 30, 5:44AM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the successful completion of the European Mutual Recognition Procedure (MRP) for AMITIZA (lubiprostone) for the treatment of chronic idiopathic constipation in select European countries, resulting in a recommendation for marketing authorization.
SCMP: 15.32 (+0.04)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Can The Uptrend Continue for Sucampo (SCMP)?
